Id: acc0528
Group: 1sens
Protein: GFAT1
Gene Symbol: GFPT1
Protein Id: Q06210
Protein Name: GFPT1_HUMAN
PTM: phosphorylation
Site: Ser243
Site Sequence: GSKFTRWGSQGERGKDKKGSC
Disease Category: Cancer
Disease: Pancreas Cancer
Disease Subtype:
Disease Cellline: MIA PaCa-2
Disease Info:
Drug: Met + 2-Deoxy-d-glucose
Drug Info: "Met: - 2-Deoxy-D-glucose is a glucose analog that acts as a competitive inhibitor of glucose metabolism by targeting hexokinase, thereby suppressing glycolysis and cellular energy production."
Effect: modulate
Effect Info: The combined treatment of 2DG and Met further enhanced the phosphorylation of AMPK and GFAT1 and significantly reduced the viability of the two pancreatic cancer cell lines.
Note: drug comb
Score: 4.0
Pubmed(PMID): 29753740
Sentence Index:
Sentence:

Sequence & Structure:

MCGIFAYLNYHVPRTRREILETLIKGLQRLEYRGYDSAGVGFDGGNDKDWEANACKIQLIKKKGKVKALDEEVHKQQDMDLDIEFDVHLGIAHTRWATHGEPSPVNSHPQRSDKNNEFIVIHNGIITNYKDLKKFLESKGYDFESETDTETIAKLVKYMYDNRESQDTSFTTLVERVIQQLEGAFALVFKSVHFPGQAVGTRRGSPLLIGVRSEHKLSTDHIPILYRTARTQIGSKFTRWGSQGERGKDKKGSCNLSRVDSTTCLFPVEEKAVEYYFASDASAVIEHTNRVIFLEDDDVAAVVDGRLSIHRIKRTAGDHPGRAVQTLQMELQQIMKGNFSSFMQKEIFEQPESVVNTMRGRVNFDDYTVNLGGLKDHIKEIQRCRRLILIACGTSYHAGVATRQVLEELTELPVMVELASDFLDRNTPVFRDDVCFFLSQSGETADTLMGLRYCKERGALTVGITNTVGSSISRETDCGVHINAGPEIGVASTKAYTSQFVSLVMFALMMCDDRISMQERRKEIMLGLKRLPDLIKEVLSMDDEIQKLATELYHQKSVLIMGRGYHYATCLEGALKIKEITYMHSEGILAGELKHGPLALVDKLMPVIMIIMRDHTYAKCQNALQQVVARQGRPVVICDKEDTETIKNTKRTIKVPHSVDCLQGILSVIPLQLLAFHLAVLRGYDVDFPRNLAKSVTVE

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

No data.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC

No intensity data of this site,
show all other sites!

GFPT1-Ser103
Cancer Intensity
BRCA 1.143
COAD
HGSC
ccRCC
GBM
HNSC -1.521
LUAD -0.687
LUSC 0.634
non_ccRCC
PDAC 0.671
UCEC -0.24
GFPT1-Ser205
Cancer Intensity
BRCA 0.083
COAD -0.261
HGSC 2.009
ccRCC
GBM
HNSC 0.106
LUAD -0.771
LUSC 0.552
non_ccRCC -1.669
PDAC 0.287
UCEC -0.335
GFPT1-Ser253
Cancer Intensity
BRCA -0.828
COAD -1.535
HGSC
ccRCC -0.048
GBM
HNSC -0.162
LUAD -0.463
LUSC 0.078
non_ccRCC 1.359
PDAC 1.69
UCEC -0.091
GFPT1-Ser257
Cancer Intensity
BRCA
COAD -0.707
HGSC 0.707
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC
GFPT1-Ser261
Cancer Intensity
BRCA -0.899
COAD 0.92
HGSC 0.98
ccRCC -1.551
GBM
HNSC 0.432
LUAD -0.633
LUSC 0
non_ccRCC
PDAC -0.652
UCEC 1.403
GFPT1-Thr262
Cancer Intensity
BRCA
COAD 0.819
HGSC 0.296
ccRCC -1.114
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC
GFPT1-Thr263
Cancer Intensity
BRCA -1.334
COAD 0.998
HGSC 0.458
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC -0.121
PDAC
UCEC

PTM-Disease Association:

source: PTMD

No data.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links: